 |
|
CLINICIAN'S CORNER
Neuroprotection in Parkinson Disease
Mysteries, Myths, and Misconceptions
Anthony H. V. Schapira, DSc, MD;
C. Warren Olanow, MD, FRCPC
JAMA. 2004;291:358-364.
Parkinson disease is an age-related neurodegenerative disease that affects approximately 1 million persons in the United States. Current therapies provide effective control of symptoms, particularly in the early stages of the disease, but most patients develop motor complications with long-term treatment, and features develop such as postural instability, falling, and dementia that are not adequately controlled with existing medications. Accordingly, neuroprotective therapy that might slow, stop, or reverse disease progression is urgently needed. While many agents appear to be promising based on laboratory studies, selecting clinical end points for clinical trials that are not confounded by symptomatic effects of the study intervention has been difficult. More recently, neuroimaging end points have been used as biomarkers of disease progression, but again there are concerns that they may be influenced by regulatory effects of the drugs used. We review clinical trials aimed at detecting neuroprotection in Parkinson disease and address the controversies surrounding the interpretation of these studies.
Author Affiliations: University Department of Clinical Neurosciences, Royal Free and University College Medical School, and Institute of Neurology, Queen Square, London, England (Dr Schapira); Department of Neurology, Mount Sinai School of Medicine, New York, NY (Dr Olanow).
RELATED LETTERS
Measuring the Effects of Therapy in Parkinson Disease
Clifford W. Shults, Richard Haas, David Oakes, Karl Kieburtz, Sandra Plumb, Ira Shoulson, M. Flint Beal, Jorge Juncos, and John Nutt
JAMA. 2004;291(20):2430-2431.
EXTRACT
| FULL TEXT
Measuring the Effects of Therapy in Parkinson Disease—Reply
C. Warren Olanow and Anthony H. V. Schapira
JAMA. 2004;291(20):2431.
EXTRACT
| FULL TEXT
RELATED ARTICLE
Parkinson Disease
Janet M. Torpy, Cassio Lynm, and Richard M. Glass
JAMA. 2004;291(3):390.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Pharmacologic Management of Parkinson Disease: Choice of Initial Therapy in Early Disease
Chen and Pahwa
Journal of Pharmacy Practice 2008;21:244-253.
ABSTRACT
A review of Parkinson's disease
Davie
Br Med Bull 2008;86:109-127.
ABSTRACT
| FULL TEXT
Specification of a Dopaminergic Phenotype from Adult Human Mesenchymal Stem Cells
Trzaska et al.
Stem Cells 2007;25:2797-2808.
ABSTRACT
| FULL TEXT
Optimized, Automated Striatal Uptake Analysis Applied to SPECT Brain Scans of Parkinson's Disease Patients
Zubal et al.
JNM 2007;48:857-864.
ABSTRACT
| FULL TEXT
Predicting Parkinson's disease: worthwhile but are we there yet?
Hawkes and Deeb
PN 2006;6:272-277.
FULL TEXT
The need for neuroprotective therapies in Parkinson's disease: A clinical perspective
Poewe
Neurology 2006;66:S2-S9.
ABSTRACT
| FULL TEXT
The pathogenesis of cell death in Parkinson's disease
Jenner and Olanow
Neurology 2006;66:S24-S36.
ABSTRACT
| FULL TEXT
Antioxidants, Supplements, and Parkinson's Disease
Weber and Ernst
The Annals of Pharmacotherapy 2006;40:935-938.
ABSTRACT
| FULL TEXT
Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials
Guimaraes et al.
Clin Trials 2005;2:509-518.
ABSTRACT
Present and future drug treatment for Parkinson's disease
Schapira
J. Neurol. Neurosurg. Psychiatry 2005;76:1472-1478.
ABSTRACT
| FULL TEXT
Moving toward whole-genome analysis: A technology perspective
Kreiner and Buck
Am J Health Syst Pharm 2005;62:296-305.
ABSTRACT
| FULL TEXT
Initial Parkinson Disease Therapy: Levodopa, Dopamine Agonists, or Both?
Roach
Arch Neurol 2004;61:1972-1973.
FULL TEXT
Measuring the Effects of Therapy in Parkinson Disease
Shults et al.
JAMA 2004;291:2430-2431.
FULL TEXT
|
